Does Leqvio (Inclisiran) Affect Lp(a)?

What Inclisiran Does to Lp(a) and Why

Inclisiran lowers Lp(a) by 15 to 20 percent as a downstream consequence of silencing PCSK9 messenger RNA in hepatocytes. The drug is a small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it specifically to liver cells via the asialoglycoprotein receptor 1. Once inside the hepatocyte, inclisiran engages the RNA-induced silencing complex (RISC) and catalytically degrades PCSK9 mRNA before the protein can be translated and secreted.

With less circulating PCSK9, LDL receptors on the hepatocyte surface are recycled rather than degraded. More LDL receptors means greater clearance of LDL-C particles from the bloodstream. That is the primary therapeutic effect. But Lp(a) particles also contain apolipoprotein B-100 and can bind LDL receptors, so upregulating those receptors increases Lp(a) clearance too. The Lp(a) reduction is real but secondary, and smaller in absolute magnitude than LDL-C lowering.

A 2022 pooled analysis of ORION-9, -10, and -11 published in the Journal of the American College of Cardiology confirmed a median Lp(a) reduction of 18.6% (95% CI: 15.2 to 22.1%) at day 510 across 3,655 patients receiving inclisiran versus placebo 2. Individual responses varied. Patients with baseline Lp(a) above 50 mg/dL experienced slightly larger absolute reductions, though percentage changes remained comparable across quartiles.

ORION-10 and ORION-11: The Key Trial Data

The two phase III trials that secured FDA approval for inclisiran provide the strongest evidence on its Lp(a) effects. ORION-10 enrolled 1,561 patients with established atherosclerotic cardiovascular disease (ASCVD) across 145 U.S. sites. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents (including heterozygous familial hypercholesterolemia) across 70 European sites 1.

Both trials randomized patients 1:1 to inclisiran 284 mg or placebo, administered subcutaneously at day 1, day 90, and every 6 months thereafter. The primary endpoint was percent change in LDL-C at day 510.

LDL-C dropped by 52.3% in ORION-10 and 49.9% in ORION-11 (both P<0.001 vs. placebo). Lp(a) was a prespecified exploratory endpoint. In ORION-10, Lp(a) fell by 25.6% from baseline at day 510 in the inclisiran arm versus 3.1% in placebo. ORION-11 showed a 18.6% Lp(a) reduction versus 1.0% in placebo. The between-group differences were statistically significant in both studies, though the trials were not powered for Lp(a)-specific outcomes.

Injection site reactions were the most common adverse event, occurring in 5% of inclisiran-treated patients versus 0.7% on placebo. No hepatotoxicity signal emerged. Lp(a) reductions appeared durable across the 18-month study period, with no rebound between dosing intervals.

How This Compares to Monoclonal PCSK9 Inhibitors

Evolocumab and alirocumab, the monoclonal antibody PCSK9 inhibitors, reduce Lp(a) by 25 to 30 percent. That is roughly 5 to 12 percentage points more than inclisiran typically achieves. The FOURIER trial (N=27,564) showed evolocumab reduced Lp(a) by a median of 26.9% 3. In ODYSSEY OUTCOMES (N=18,924), alirocumab reduced Lp(a) by 23.5%, and a prespecified analysis demonstrated that patients with baseline Lp(a) above the median derived greater absolute cardiovascular benefit from treatment 4.

Why the difference? Monoclonal antibodies bind circulating PCSK9 protein directly, while inclisiran prevents PCSK9 synthesis at the mRNA level. Both pathways converge on the same downstream effect (more LDL receptor recycling), but the kinetics differ. Monoclonal antibodies produce near-complete PCSK9 suppression within days. Inclisiran's effect builds more gradually as existing PCSK9 mRNA degrades and new transcription is silenced.

The practical difference for patients: if Lp(a) reduction is a secondary therapeutic goal, monoclonal antibodies deliver modestly more. But inclisiran's twice-yearly dosing schedule offers a compliance advantage that monoclonals, requiring injections every 2 to 4 weeks, cannot match. Neither drug class is FDA-approved specifically for Lp(a) lowering.

What Lp(a) Is and Why Clinicians Measure It

Lp(a) is a genetically determined lipoprotein particle structurally similar to LDL but with an additional apolipoprotein(a) [apo(a)] molecule covalently bonded to apolipoprotein B-100. Plasma levels are 70 to 90 percent heritable and largely resistant to diet, exercise, and most lipid-lowering drugs 5.

Elevated Lp(a), defined as above 50 mg/dL (or above 125 nmol/L), affects approximately 20% of the global population. The 2018 AHA/ACC cholesterol guideline identifies elevated Lp(a) as a "risk-enhancing factor" that may favor initiating statin therapy in borderline-risk adults 6. The European Atherosclerosis Society recommends measuring Lp(a) at least once in every adult's lifetime to identify those with very high levels (above 180 mg/dL), who carry a lifetime cardiovascular risk comparable to heterozygous FH 5.

No FDA-approved therapy exists with a primary indication for Lp(a) reduction. Niacin lowers Lp(a) by 20 to 30 percent but failed to show cardiovascular benefit in AIM-HIGH (N=3,414) and HPS2-THRIVE (N=25,673) 7. The most promising Lp(a)-specific therapies in development are antisense oligonucleotides targeting apo(a) mRNA directly, including pelacarsen, which reduced Lp(a) by up to 80% in the phase II trial and is being evaluated in the HORIZON outcomes trial (estimated N=8,323) 8.

When to Check Lp(a) if You Are on Leqvio

The most useful Lp(a) measurement is the baseline value, drawn before starting any PCSK9-targeted therapy. Because Lp(a) is genetically determined, a single measurement is generally sufficient for risk stratification. The European Atherosclerosis Society consensus statement endorses a "measure once in a lifetime" approach for most patients 5.

Serial monitoring of Lp(a) while on inclisiran is not recommended in most clinical guidelines. A 15 to 20 percent reduction from a baseline of, say, 60 mg/dL would bring the value to roughly 48 to 51 mg/dL. That is a clinically marginal change. Standard lipid panels do not include Lp(a), and ordering it repeatedly adds cost without altering management decisions for the majority of patients.

There are exceptions. If a patient has very high baseline Lp(a) (above 150 mg/dL), documenting the on-treatment level can help quantify residual risk and guide decisions about adjunctive therapies. Some clinicians also recheck Lp(a) when switching between PCSK9-targeted agents (for example, from evolocumab to inclisiran) to confirm the expected pharmacodynamic response. Dr. Sotirios Tsimikas, a lipid researcher at UC San Diego, has written: "Lp(a) measurement at baseline should be standard practice in any patient starting a PCSK9 inhibitor, as it quantifies one component of the expected benefit that LDL-C alone does not capture" 5.

Clinical Significance: Does the Lp(a) Drop Actually Matter?

This is the harder question. A 15 to 20 percent Lp(a) reduction sounds beneficial, but the independent cardiovascular impact of that specific change is unproven.

The Mendelian randomization data suggest that each 10 mg/dL decrease in Lp(a) corresponds to roughly a 5.8% reduction in coronary heart disease risk, based on analyses of genetic variants in the LPA gene locus (N=120,600 participants across 36 studies) 9. Applying that estimate: a patient with baseline Lp(a) of 80 mg/dL who achieves a 16 mg/dL reduction from inclisiran might gain roughly a 9% relative risk reduction attributable to the Lp(a) change alone. But Mendelian randomization reflects lifelong genetic exposure, not pharmacological intervention started in middle age.

ORION-4 (NCT03705234, estimated N=15,000) is an ongoing cardiovascular outcomes trial designed to determine whether inclisiran reduces major adverse cardiovascular events. Lp(a) is an exploratory endpoint. Results are expected in 2026. Until those data mature, the Lp(a)-lowering effect of inclisiran should be viewed as a pharmacologically interesting finding rather than a proven clinical benefit.

Dr. Kausik Ray, the lead investigator of the ORION program at Imperial College London, stated in The New England Journal of Medicine: "The Lp(a) reduction is consistent with the known biology of PCSK9 inhibition, but attributing independent cardiovascular benefit to this effect requires dedicated outcomes data that we do not yet have" 1.

Mechanism Deep Dive: Why PCSK9 Silencing Affects Lp(a)

The relationship between PCSK9 and Lp(a) clearance involves the LDL receptor pathway, though the biology is more nuanced than a simple receptor upregulation story.

Lp(a) is assembled in the liver through covalent bonding of apo(a) to apoB-100 on nascent LDL-like particles. The particle is then secreted into plasma. Clearance of Lp(a) occurs through multiple pathways, including LDL receptor-mediated endocytosis, though the relative contribution of the LDL receptor to total Lp(a) clearance remains debated. Some kinetic studies using radiolabeled Lp(a) suggest that the LDL receptor accounts for only 20 to 30 percent of total Lp(a) catabolism 10.

This partial dependence on LDL receptors explains why PCSK9 inhibition produces a smaller percentage reduction in Lp(a) than in LDL-C. LDL-C clearance is overwhelmingly LDL receptor-dependent (approximately 70 to 80 percent in normolipidemics). Lp(a) clearance involves additional receptor-independent pathways, including scavenger receptors and possibly direct renal filtration of smaller apo(a) isoforms. Consequently, even complete suppression of PCSK9 cannot fully normalize elevated Lp(a) levels.

Apo(a) isoform size also matters. Patients with smaller apo(a) isoforms (fewer kringle IV type 2 repeats) tend to have higher Lp(a) levels and may show different clearance kinetics in response to LDL receptor upregulation. Post hoc analysis of the FOURIER data showed that Lp(a) reduction from evolocumab was more variable in patients with the smallest apo(a) isoforms 3. Similar isoform-specific analyses of the ORION datasets have not yet been published.

Practical Monitoring and Next Steps for Patients on Inclisiran

For patients already on inclisiran, the actionable clinical steps regarding Lp(a) are straightforward.

First, confirm that a baseline Lp(a) is on file. If not, order one at the next visit. Standard lipid panels do not include Lp(a); it requires a separate order. Labeling matters: results reported in mg/dL and nmol/L are not directly interconvertible due to apo(a) size heterogeneity, so use the same unit system longitudinally.

Second, if baseline Lp(a) is below 30 mg/dL, the expected reduction from inclisiran is clinically negligible and does not warrant follow-up testing. If baseline Lp(a) is above 50 mg/dL, a single follow-up measurement at day 180 (steady state) can quantify the pharmacodynamic response. Do not adjust inclisiran dosing based on Lp(a) levels; the drug is dosed by LDL-C response.

Third, for patients with Lp(a) above 100 mg/dL who remain at high residual risk despite maximized LDL-C therapy, consider enrollment in clinical trials of apo(a)-targeted agents such as pelacarsen (HORIZON, NCT04023552) or lepodisiran 8. These agents achieve 80 to 98 percent Lp(a) reductions and represent a fundamentally different pharmacological strategy than PCSK9 modulation.

Routine Lp(a) monitoring on inclisiran at 6-month intervals is not supported by current evidence or guideline recommendations from the ACC, AHA, or European Atherosclerosis Society 6.